Gregoire Chevalier
CEO,
Atopia Therapeutics
Switzerland
Grégoire Chevalier is the CEO of Atopia Therapeutics, a Geneva-based biotech company pioneering a novel oral immunotherapy for allergic diseases. With a strong background in immunology and translational research, he has extensive expertise in early-stage drug development and biotech entrepreneurship.
Grégoire began his scientific career with a PhD in neuroimmunology and pursued with a postdoctoral fellowship at the Institut Pasteur, where he focused on immune regulation and microbiome-host interactions. Than, he joined Enterome, a French biotech company focusing in immuno-oncology and inflammatory bowel diseases, where he led several R&D programs to the clinic.
Now leading Atopia’s Series A fundraising, Grégoire is focused on advancing the company’s preclinical and early clinical development to bring a first-in-class, disease-modifying treatment to patients. He is actively engaging with investors and pharmaceutical partners to accelerate Atopia’s progress and address the growing burden of allergic diseases with a transformative new therapy. Passionate about scientific innovation and patient impact, Grégoire is committed to shaping the future of allergy treatment through cutting-edge biotechnology.
Suffix
PhD
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}